Why Is Pet Health Company IDEXX Laboratories Stock Trading Higher On Monday?
1. IDXX reported Q4 adjusted EPS of $2.53, beating consensus estimates. 2. Sales reached $954.3 million, exceeding forecasts of $934.99 million. 3. CAG Diagnostics recurring revenue grew 6%, benefiting from high customer retention. 4. Operating margin improved to 27.4%, indicating strong financial stability. 5. 2025 revenue outlook of $4.055-$4.170 billion reflects expected growth.